Bionano Genomics Inc
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It als… Read more
Bionano Genomics Inc (BNGO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.119x
Based on the latest financial reports, Bionano Genomics Inc (BNGO) has a cash flow conversion efficiency ratio of -0.119x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.92 Million) by net assets ($49.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bionano Genomics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Bionano Genomics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bionano Genomics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bionano Genomics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NextCell Pharma AB
ST:NXTCL
|
-0.162x |
|
J.S.P. Property Public Company Limited
BK:JSP
|
0.025x |
|
Airthings ASA
PINK:ARTGF
|
-0.038x |
|
Eureka Design Public Company Limited
BK:UREKA
|
0.002x |
|
Dongsung Pharm
KO:002210
|
0.104x |
|
Chonburi Concrete Product Public Company Limited
BK:CCP
|
0.074x |
|
Cadence Opportunities Fund Ltd
AU:CDO
|
0.000x |
|
IRLAB THERAP. AB A
F:6IRA
|
N/A |
Annual Cash Flow Conversion Efficiency for Bionano Genomics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Bionano Genomics Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $35.38 Million | $-68.92 Million | -1.948x | -49.66% |
| 2023-12-31 | $96.16 Million | $-125.18 Million | -1.302x | -160.12% |
| 2022-12-31 | $249.40 Million | $-124.82 Million | -0.500x | -134.57% |
| 2021-12-31 | $337.12 Million | $-71.93 Million | -0.213x | +80.46% |
| 2020-12-31 | $35.08 Million | $-38.31 Million | -1.092x | +86.64% |
| 2019-12-31 | $3.61 Million | $-29.53 Million | -8.172x | -315.36% |
| 2018-12-31 | $10.14 Million | $-19.94 Million | -1.967x | -574.67% |
| 2017-12-31 | $-50.23 Million | $-20.82 Million | 0.414x | -51.92% |
| 2016-12-31 | $-27.26 Million | $-23.50 Million | 0.862x | -- |